Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 21874303 | HLA-A*02 | prostate cancer | NA | NA | NA | unclassified | |
| ctl specific for the hla-a*0201-restricted klk4 peptide were more readily expanded to a higher frequency in vitro compared to the known hla-a*0201-restricted epitopes from prostate cancer antigens; prostate-specific antigen (psa), prostate-specific membrane antigen (psma) and prostatic acid phosphatase (pap). | |||||||
| 22487023 | HLA-CLASS I (HLA CLASS II) | prostate cancer | NA | NA | NA | unclassified | |
| analysis of kir gene frequencies and hla class i genotypes in prostate cancer and control group. | |||||||
| 22487023 | HLA (HLA) | prostate cancer | NA | NA | NA | unclassified | |
| the aim of our study is to evaluate the association between the kir genes and hla alleles in patients with prostate cancer and healthy controls. | |||||||
| 22487023 | HLA-CLASS I (HLA CLASS II) | prostate cancer | NA | NA | NA | unclassified | |
| two hundred patients with prostate cancer and 185 healthy controls were typed for hla class i and kir genes by pcr-ssp. | |||||||
| 22512631 | HLA-A*02 | prostate cancer | NA | NA | NA | unclassified | |
| a novel method of coordinated intraprostatic, autologous dendritic cell injection together with radiation therapy was prospectively evaluated in five hla-a2(+) subjects with high-risk, localized prostate cancer, using androgen suppression, 45 gy external beam radiation therapy in 25 fractions over 5 weeks, dendritic cell injections after fractions 5, 15 and 25 and then interstitial radioactive seed placement. | |||||||
| 22529020 | HLA-DRB1*01 | prostate cancer | NA | NA | NA | unclassified | |
| t cells specific for one epitope (pap(181-195) ) were found to be augmented after immunization in a hla-drb1*0101+ prostate cancer patient. | |||||||
| 22529020 | MHC (MHC) | prostate cancer | NA | NA | NA | only_studied | |
| the identification of mhc class ii epitopes may provide tools to directly monitor immune responses after vaccination and may be important for the design of future prostate cancer vaccines. | |||||||
| 22862954 | HLA-A*02 | prostate cancer | NA | NA | NA | unclassified | |
| naturally processed hla-a2 restricted peptides presented by breast, ovarian and prostate cancer cells were used as antigens to create a therapeutic cancer vaccine, dpx-0907. | |||||||
| 22993607 | HLA-A*24 | prostate cancer | NA | NA | NA | unclassified | |
| a b-tubulin 5-derived peptide induces cytotoxic t lymphocytes restricted to the hla-a24 allele in prostate cancer patients. | |||||||
| 22993607 | HLA-A*31 | prostate cancer | NA | NA | NA | unclassified | |
| to facilitate the development of a peptide-based cancer vaccine for prostate cancer patients, we examined whether any of the 13 peptides previously reported to induce hla-class i-restricted cytotoxic t lymphocyte (ctl) activity in hla-a3 supertype (-a3, -a11, -a31 and -a33)-positive prostate cancer patients are also capable of inducing ctls restricted to hla-a2, hla-a24 or hla-a26 alleles. | |||||||
Copyright 2024